Procter & Gambl...
Health Care: Drugs
Affymax Inc. (AFFY: NASDAQ)
$1.39 -0.01 | -0.71%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.39 |
| 52 Week High | 27.74 |
| 52 Week Low | 0.78 |
| Avg. Daily Vol. (Mil) | 9.65 |
| Beta (3 year) | 1.47 |
| Share Related Items | |
| Mkt Cap (Mil) | 52.11 |
| Shares Out (Mil) | 37.49 |
| Float (Mil) | 37.45 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.80 |
| Current Ratio | 0.80 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 1.63 |
| Price/Book | 0.00 |
| Price/Cash Flow | -0.30 |
| Per Share Data | |
| Earnings | -4.15 |
| Sales | 0.85 |
| Book Value | 0.00 |
| Cash Flow | -4.00 |
| Business Summary | |
|---|---|
| Affymax, Inc., is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. | |
| General Information | |
| 4001 Miranda Avenue
Palo Alto, CA 94304 |
|
| www.affymax.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 304 | |
| CEO: | |
| Short Interest | |
| Current Month (Mil) | 12.93 |
| Previous Month (Mil) | 15.83 |
| Short Interest Ratio (Days) | 5.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -227.90 |
| Return on Investments | 1,029.00 |
| Profitability | |
| Gross Margin | -34.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with AFFY
- Portfolio NameUser Type
- ContributorMost-Active Stocks for the ...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
Latest AFFY Headlines from TheStreet
- Commit To Buy Affymax At $1, Earn 45.8% Annualized 05.24.13 | 01:05 pm
- 4 Hot Stocks to Trade (or Not) 05.09.13 | 01:05 pm
- 2 Drug Stocks Under $10 To Pick As Favorites 03.25.13 | 02:03 pm
- 5 Big Stocks to Trade (or Not) 03.19.13 | 02:03 pm
- 4 Biotech Stocks Under $5 to Watch 03.15.13 | 07:03 am
- Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharm 03.15.13 | 06:03 am
- 5 Stocks Ready to Break Out 03.08.13 | 02:03 pm
- 5 Stocks Poised for Breakouts 03.01.13 | 02:03 pm
- 3 Stocks Pushing The Drugs Industry Lower 02.25.13 | 12:02 pm
- Affymax Is Done. RIP. 02.25.13 | 10:02 am
Press Releases for AFFY
- UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors With Losses On Their Investment In Affymax, Inc. Of Class Action Lawsuit And The Deadline Of April 29, 2013 To Seek A Lead Plaintiff Position - PR Newswire 04.23.13 | 03:04 pm
- Harwood Feffer LLP Announces Investigation Of Affymax, Inc. - PR Newswire 04.03.13 | 04:04 pm
- Lifshitz Law Firm Announces Class Action Lawsuits Against Affymax, Inc., Impax Laboratories Inc., And Tangoe, Inc. - PR Newswire 03.18.13 | 07:03 pm
- Affymax Announces Reduction In Force To Align Resources Around Ongoing Product Investigation - Business Wire 03.18.13 | 05:03 pm
- Lawyers Seek To Restore Investors' Losses And Confidence In Affymax, Announces Deans & Lyons Law Firm LLP - Business Wire 03.11.13 | 02:03 pm
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Affymax, Inc. To Contact The Firm - PR Newswire 03.01.13 | 09:03 pm
- A Securities Fraud Class Action Lawsuit Has Been Filed Against Affymax, Inc., Shareholders Are Encouraged To Contact Holzer Holzer & Fistel, LLC - Business Wire 02.28.13 | 12:02 pm
- Finkelstein Thompson LLP Announces Investigation Of Affymax, Inc. - Business Wire 02.27.13 | 05:02 pm
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Affymax, Inc. - PR Newswire 02.25.13 | 10:02 am
- Affymax Announces Teleconference And Webcast - Business Wire 02.25.13 | 08:02 am
Partner Headlines for AFFY
- Affymax Earnings:Here’s Why the Stock is Falling Now - Wall St. Cheat Sheet 04.02.13 | 12:04 pm
- Will Affymax’s Loss Annoy These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.02.13 | 12:04 pm
- Pre-Market Most Active for Mar 12, 2013 : ZNGA, GLUU, BBRY, SNE, MRK, BCS, MT, GOV, BAC, ARMH, AAPL, AFFY - NASDAQ 03.12.13 | 12:03 pm
- FDA Recalls Affymax Omontys - Benzinga 03.08.13 | 07:03 pm
- Pre-Market Most Active for Mar 8, 2013 : BAC, BCS, QQQ, C, NOK, V, GDI, AFFY, SKUL, HOTT, FB, BBRY - NASDAQ 03.08.13 | 01:03 pm
- Pre-Market Most Active for Feb 26, 2013 : SAN, BBVA, TEF, BAC, FTE, SNY, ZNGA, SIRI, AFFY, VVUS, BBRY, FB - NASDAQ 02.26.13 | 01:02 pm
- After Hours Most Active for Feb 25, 2013 : QQQ, BAC, SIRI, MT, XOM, NLY, T, FB, AA, AFFY, INTC, MSFT - NASDAQ 02.25.13 | 09:02 pm
- Stocks Stay Down, Near Day's Lows, But Amgen Hits High - Investor's Business Daily 02.25.13 | 03:02 pm
- Pre-Market Most Active for Feb 25, 2013 : AFFY, ZNGA, BAC, VOD, BBRY, ELN, ING, NOK, BCS, BP, FB, SIRI - NASDAQ 02.25.13 | 01:02 pm
- Beat and Raise Quarter for Amgen - Analyst Blog - Zacks 10.24.12 | 09:10 am
